Feld, 60 patient peginterferon lambda early treatment RCT: 75% lower progression [p=0.35] and 66% improved viral clearance [p=0.03] https://c19p.org/feld
copied to clipboard
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30566-X (preprint 11/12/2020)
Small outpatient RCT with 30 peginterferon lambda and 30 control patients, showing improved viral clearance with treatment. Single subcutaneous injection of peginterferon lambda 180μg. NCT04354259.
|
risk of hospitalization, no change, RR 1.00, p = 1.00, treatment 1 of 30 (3.3%), control 1 of 30 (3.3%).
|
|
risk of ER visit, 75.0% lower, RR 0.25, p = 0.35, treatment 1 of 30 (3.3%), control 4 of 30 (13.3%), NNT 10.0.
|
|
risk of no viral clearance, 66.4% lower, RR 0.34, p = 0.03, treatment 6 of 30 (20.0%), control 11 of 30 (36.7%), NNT 6.0, odds ratio converted to relative risk, adjusted for baseline viral load, day 7.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Feld et al., 11/12/2020, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, North America, peer-reviewed, 35 authors, study period 18 May, 2020 - 4 September, 2020, average treatment delay 4.3 days, trial NCT04354259.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.